Living donor liver transplantation for combined hepatocellular-cholangiocarcinoma: A case series of four patients.
Combined hepatocellular-cholangiocarcinoma
Hepatocellular carcinoma
Liver transplantation
Journal
International journal of surgery case reports
ISSN: 2210-2612
Titre abrégé: Int J Surg Case Rep
Pays: Netherlands
ID NLM: 101529872
Informations de publication
Date de publication:
2020
2020
Historique:
received:
03
06
2020
revised:
14
07
2020
accepted:
21
07
2020
pubmed:
14
8
2020
medline:
14
8
2020
entrez:
14
8
2020
Statut:
ppublish
Résumé
Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a rare primary liver carcinoma whose components include both hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA). Indications for liver transplantation for cHCC-CCA remain controversial. Four patients underwent living donor liver transplantation (LDLT) for cHCC-CCA. All patients had multiple tumor nodules preoperatively diagnosed as HCC. Postoperative pathological examinations revealed that one of the tumors was cHCC-CCA. Cases 1 and 2 underwent LDLT for cirrhosis with HCC tumors that met Milan criteria. Case 3 underwent LDLT for recurrent HCC tumors with nonalcoholic steatohepatitis. Although the preoperative examinations showed that the patient met the Kyoto, but not Milan criteria, postoperative pathological examinations revealed that the patient did meet Milan criteria. The three patients who met Milan criteria on postoperative pathological examination had no recurrences after LDLT. Case 4 had multiple tumors with alcoholic liver cirrhosis. Although the preoperative examinations showed that the patient did not meet Milan criteria-but did meet Kyoto criteria-, on postoperative pathological examinations, the patient met neither Millan nor Kyoto criteria. He died of tumor recurrence 15 months after LDLT. Our experiences suggested that patients who meet Millan or Kyoto criteria experienced acceptable outcomes of LDLT for cHCC-CCA. By itself, cHCC-CCA is not contraindication for liver transplantation.
Identifiants
pubmed: 32791447
pii: S2210-2612(20)30580-0
doi: 10.1016/j.ijscr.2020.07.069
pmc: PMC7424173
pii:
doi:
Types de publication
Journal Article
Langues
eng
Pagination
46-52Informations de copyright
Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Références
Int J Surg. 2018 Dec;60:279-282
pubmed: 30359781
Surg Today. 2017 Aug;47(8):908-917
pubmed: 28124125
Am J Transplant. 2010 May;10(5):1263-7
pubmed: 20420633
Cancer. 1985 Jan 1;55(1):124-35
pubmed: 2578078
Liver Transpl. 2014 Aug;20(8):952-9
pubmed: 24777610
Ann Transplant. 2017 Feb 28;22:115-120
pubmed: 28242867
Liver Transpl. 2017 Mar;23(3):330-341
pubmed: 28027599
Liver Transpl. 2007 Dec;13(12):1637-44
pubmed: 18044766
AJR Am J Roentgenol. 2013 Aug;201(2):332-9
pubmed: 23883213
N Engl J Med. 1996 Mar 14;334(11):693-9
pubmed: 8594428
HPB (Oxford). 2016 Jan;18(1):29-34
pubmed: 26776848
Eur J Radiol Open. 2014 Sep 06;1:40-8
pubmed: 26937426
Am J Pathol. 1949 Jul;25(4):647-55
pubmed: 18152860
Nat Rev Dis Primers. 2016 Apr 14;2:16018
pubmed: 27158749
J Surg Oncol. 2013 May;107(6):608-12
pubmed: 23386397
J Gastroenterol Hepatol. 2013 Jan;28(1):122-7
pubmed: 23034166
AJR Am J Roentgenol. 2016 Jul;207(1):25-31
pubmed: 26866746
Ann Surg Oncol. 2012 Sep;19(9):2869-76
pubmed: 22451237